The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Open accessAbstract
Combining venetoclax, a selective BCL2 inhibitor, with low-dose navitoclax, a BCL-XL/BCL2 inhibitor, may allow targeting of both BCL2 and BCL-XL without dose-limiting thrombocytopenia associated with navitoclax monotherapy. The safety and preliminary efficacy of venetoclax with low-dose navitoclax and chemotherapy was assessed in this phase I dose-escalation study (NCT03181126) in pediatric and adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia or lymphoblastic lymphoma. Forty-seven patients received treatment. A recommended phase II dose of 50 mg navitoclax for adults and 25 mg for patients <45 kg with 400 mg adult-equivalent venetoclax was identified. Delayed hematopoietic recovery was the primary safety finding. The complete remission rate was 60%, including responses in patients who had previously received hematopoietic cell transplantation or immunotherapy. Thirteen patients (28%) proceeded to transplantation or CAR T-cell therapy on study. Venetoclax with navitoclax and chemotherapy was well tolerated and had promising efficacy in this heavily pretreated patient population. Significance: In this phase I study, venetoclax with low-dose navitoclax and chemotherapy was well tolerated and had promising efficacy in patients with relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma. Responses were observed in patients across histologic and genomic subtypes and in those who failed available therapies including stem cell transplant. See related commentary by Larkin and Byrd, p. 1324. This article is highlighted in the In This Issue feature, p. 1307
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Near-optimal probabilistic RNA-seq quantification
Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3519 · Cited by 9,723
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citationCheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Quality control and preprocessing of metagenomic datasets
Schmieder, R., & Edwards, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr026 · Cited by 5,072
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationAppio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
BCL-2 family proteins: changing partners in the dance towards death
Kale, J., Osterlund, E. J., & Andrews, D. W. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.186 · Cited by 1,574
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Martinelli, G., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S., Wang, K., Wang, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509277 · Cited by 1,413
Self-citationProgrammed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · cited 1×
“In phase I studies of patients with relapsed/refractory lymphoid 151 malignancies, including CLL and non-Hodgkin lymphoma, navitoclax was associated with 152 clinical activity, though thrombocytopenia, due to on-target BCL-XL inhibition, (26) was common 153 and dose limiting (24,25).”
BackgroundEarly T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
Coustan-Smith, E., Mullighan, C. G., Onciu, M., Behm, F. G., Raimondi, S. C., Pei, D., Cheng, C., Su, X., Rubnitz, J. E., Basso, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70314-0 · Cited by 1,019
Self-citationWilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876
Self-citationRoberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 830
Self-citationPAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
Gu, Z., Churchman, M. L., Roberts, K. G., Moore, I., Zhou, X., Nakitandwe, J., Hagiwara, K., Pelletier, S., Gingras, S., Berns, H., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0315-5 · Cited by 603
Self-citationStock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., Willman, C. L., Fulton, N., Laumann, K. M., Malnassy, G., et al. (2019) · Blood · doi:10.1182/blood-2018-10-881961 · Cited by 488
Self-citationResults of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia
Toft, N., Birgens, H., Abrahamsson, J., Griškevičius, L., Hallböök, H., Heyman, M., Klausen, T. W., Jónsson, Ó., Palk, K., Pruunsild, K., et al. (2018) · Leukemia · doi:10.1038/leu.2017.265 · Cited by 409
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins
Konopleva, M., Konoplev, S., Hu, W., Zaritskey, A., Afanasiev, B., & Andreeff, M. (2002) · Leukemia · doi:10.1038/sj.leu.2402608 · Cited by 389
FusionCatcher – a tool for finding somatic fusion genes in paired-end RNA-sequencing data
Nicorici, D., Şatalan, M., Edgren, H., Kangaspeska, S., Murumägi, A., Kallioniemi, O., Virtanen, S., & Kilkku, O. (2014) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/011650 · Cited by 388
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
Jain, N., Roberts, K. G., Jabbour, E., Patel, K., Eterovic, A. K., Chen, K., Zweidler-McKay, P., Lu, X., Fawcett, G., Wang, S. A., et al. (2017) · Blood · doi:10.1182/blood-2016-07-726588 · Cited by 387
Self-citationVo, T.-T., Ryan, J., Carrasco, R., Neuberg, D., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 348
Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., Liedtke, M., Stock, W., Gökbuget, N., O’Brien, S. M., Jabbour, E., Wang, T., Liang White, J., et al. (2019) · Cancer · doi:10.1002/cncr.32116 · Cited by 343
Self-citationMcl-1 is a potential therapeutic target in multiple types of cancer
Akgul, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8637-6 · Cited by 329
Genomics in acute lymphoblastic leukaemia: insights and treatment implications
Roberts, K. G., & Mullighan, C. G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.38 · Cited by 287
Self-citationKo, R. H., Ji, L., Barnette, P., Bostrom, B., Hutchinson, R., Raetz, E., Seibel, N. L., Twist, C. J., Eckroth, E., Sposto, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2950 · Cited by 281
Chonghaile, T. N., Roderick, J. E., Glenfield, C., Ryan, J., Sallan, S. E., Silverman, L. B., Loh, M. L., Hunger, S. P., Wood, B., DeAngelo, D. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0353 · Cited by 275
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia
Del Gaizo Moore, V., Schlis, K. D., Sallan, S. E., Armstrong, S. A., & Letai, A. (2008) · Blood · doi:10.1182/blood-2007-06-098012 · Cited by 223
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Cited by 180
Self-citationKang, M. H., Kang, Y. H., Szymanska, B., Wilczynska-Kalak, U., Sheard, M. A., Harned, T. M., Lock, R. B., & Reynolds, C. P. (2007) · Blood · doi:10.1182/blood-2007-03-080325 · Cited by 178
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
Khaw, S. L., Suryani, S., Evans, K., Richmond, J., Robbins, A., Kurmasheva, R. T., Billups, C. A., Erickson, S. W., Guo, Y., Houghton, P. J., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707414 · Cited by 174
Self-citationKarol, S. E., Alexander, T. B., Budhraja, A., Pounds, S. B., Canavera, K., Wang, L., Wolf, J., Klco, J. M., Mead, P. E., Das Gupta, S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30060-7 · Cited by 163
Self-citationOutcome of adults with acute lymphocytic leukemia after second salvage therapy
O'Brien, S. M., Thomas, D. M., Ravandi, F., Faderl, S. H., Cortes, J. E., Borthakur, G., Pierce, S. A., Garcia‐Manero, G., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23919 · Cited by 150
Ryan, J. A., Montero, J., Rocco, J. W., & Letai, A. G. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0107 · Cited by 139
Richard‐Carpentier, G., Jabbour, E. J., Short, N. J., Rausch, C. R., Savoy, J. M., Bose, P., Yilmaz, M. E., Jain, N., Borthakur, G. M., Ohanian, M. N., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.608 · Cited by 139
Self-citationInitial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program
Lock, R. B., Carol, H., Houghton, P. J., Morton, C. L., Kolb, E. A., Gorlick, R. G., Reynolds, C. P., Maris, J. M., Keir, S. T., Wu, J., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21433 · Cited by 131
BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Alford, S. E., Kothari, A., Loeff, F. C., Eichhorn, J. M., Sakurikar, N., Goselink, H. M., Saylors, R. L., Jedema, I., Falkenburg, J. H. F., & Chambers, T. C. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1849 · Cited by 127
High, L. M., Szymanska, B., Wilczynska-Kalak, U., Barber, N., O’Brien, R., Khaw, S. L., Vikstrom, I. B., Roberts, A. W., & Lock, R. B. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.060780 · Cited by 126
Self-citationDouer, D., Aldoss, I. T., Lunning, M. A., Burke, P. W., Ramezani, L., Mark, L., Vrona, J., Park, J. H., Tallman, M. S., Avramis, V. I., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.2708 · Cited by 123
Self-citationSuryani, S., Carol, H., Chonghaile, T. N., Frismantas, V., Sarmah, C. K., High, L. M., Bornhauser, B. C., Cowley, M. J., Szymanska, B., Evans, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0259 · Cited by 95
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia
Leonard, J. T., Rowley, J., Eide, C. A., Traer, E. A., Hayes‐Lattin, B., Loriaux, M., Spurgeon, S. E. F., Druker, B. J., Tyner, J. W., & Chang, B. H. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5309 · Cited by 87
Self-citationBcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia
Díaz-Flores, E., Comeaux, E. Q., Kim, K. L., Melnik, E., Beckman, K., Davis, K. L., Wu, K. J., Akutagawa, J., Bridges, O. A., Marino, R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-0236 · Cited by 78
Self-citationEarl, M. A. (2009) · PubMed · Cited by 61
Kadia, T. M., & Gandhi, V. V. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2017.1262757 · Cited by 54
The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
McBride, A., Houtmann, S., Wilde, L. R., Vigil, C. E., Eischen, C. M., Kasner, M. T., & Palmisiano, N. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00192 · Cited by 53
Numan, Y., Alfayez, M., Maiti, A., Alvarado, Y., Jabbour, E. J., Ferrajoli, A., Konoplev, S. N., Kantarjian, H. M., & Bose, P. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00127 · Cited by 51
Self-citation
Cited by
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Vogler, M., Braun, Y., Smith, V. M., Westhoff, M.-A., Pereira, R. S., Pieper, N. M., Anders, M., Callens, M., Vervliet, T., Abbas, M., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02176-0 · Cited by 462
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 346
BH3 Mimetics in Hematologic Malignancies
Klener, P., Sovilj, D., Renesova, N., & Andera, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810157 · Cited by 31
Proteolysis targeting chimeras as senolytics: An emerging senotherapy for combating aging
Cruickshank-Taylor, A. B., Kozora, J. S., Carew, J. S., Nawrocki, S. T., & Wang, W. (2025) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103752 · Cited by 4
Metadata
- Authors
- Pullarkat, V. A., Lacayo, N. J., Jabbour, E., Rubnitz, J. E., Bajel, A., Laetsch, T. W., Leonard, J., Colace, S. I., Khaw, S. L., Fleming, S. A., Mattison, R. J., Norris, R., Opferman, J. T., Roberts, K. G., Zhao, Y., Qu, C., Badawi, M., Schmidt, M., Tong, B., Pesko, J. C., Sun, Y., Ross, J. A., Vishwamitra, D., Rosenwinkel, L., Kim, S. Y., Jacobson, A., Mullighan, C. G., Alexander, T. B., & Stock, W.
- Venue
- Cancer Discovery
- Published
- 2021-02-16
- Volume
- 11
- Issue
- 6
- Pages
- 1440-1453
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3131213086
- Cited by
- 302
- References
- 48
- FWCI
- 38.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.